PDF(Pubmed)
Abstract：
BACKGROUND: Severe acute pancreatitis (SAP) is a dangerous condition with a high mortality rate. Many studies have found an association between adipokines and the development of SAP, but the results are controversial. Therefore, we performed a meta-analysis of the association of inflammatory adipokines with SAP.
METHODS: We screened PubMed, EMBASE, Web of Science and Cochrane Library for articles on adipokines and SAP published before July 20, 2023. The quality of the literature was assessed using QUADAS criteria. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated to assess the combined effect. Subgroup analysis, sensitivity analysis and publication bias tests were also performed on the information obtained.
RESULTS: Fifteen eligible studies included 1332 patients with acute pancreatitis (AP). Pooled analysis showed that patients with SAP had significantly higher serum levels of resistin (SMD = 0.78, 95% CI:0.37 to 1.19, z = 3.75, P = 0.000). The difference in leptin and adiponectin levels between SAP and mild acute pancreatitis (MAP) patients were not significant (SMD = 0.30, 95% CI: -0.08 to 0.68, z = 1.53, P = 0.127 and SMD = 0.11, 95% CI: -0.17 to 0.40, z = 0.80, P = 0.425, respectively). In patients with SAP, visfatin levels were not significantly different from that in patients with MAP (SMD = 1.20, 95% CI: -0.48 to 2.88, z = 1.40, P = 0.162).
CONCLUSIONS: Elevated levels of resistin are associated with the development of SAP. Resistin may serve as biomarker for SAP and has promise as therapeutic target.
METHODS: We screened PubMed, EMBASE, Web of Science and Cochrane Library for articles on adipokines and SAP published before July 20, 2023. The quality of the literature was assessed using QUADAS criteria. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated to assess the combined effect. Subgroup analysis, sensitivity analysis and publication bias tests were also performed on the information obtained.
RESULTS: Fifteen eligible studies included 1332 patients with acute pancreatitis (AP). Pooled analysis showed that patients with SAP had significantly higher serum levels of resistin (SMD = 0.78, 95% CI:0.37 to 1.19, z = 3.75, P = 0.000). The difference in leptin and adiponectin levels between SAP and mild acute pancreatitis (MAP) patients were not significant (SMD = 0.30, 95% CI: -0.08 to 0.68, z = 1.53, P = 0.127 and SMD = 0.11, 95% CI: -0.17 to 0.40, z = 0.80, P = 0.425, respectively). In patients with SAP, visfatin levels were not significantly different from that in patients with MAP (SMD = 1.20, 95% CI: -0.48 to 2.88, z = 1.40, P = 0.162).
CONCLUSIONS: Elevated levels of resistin are associated with the development of SAP. Resistin may serve as biomarker for SAP and has promise as therapeutic target.
摘要：
背景：重症急性胰腺炎（SAP）是一种危险的疾病，死亡率很高。许多研究发现脂肪因子与SAP的发展之间存在关联，但是结果是有争议的。因此,我们对炎性脂肪因子与SAP的相关性进行了荟萃分析.
方法：我们筛选了PubMed，EMBASE,WebofScienceandCochraneLibraryforarticlesonadipokinesandSAPbeforeJuly20,2023.使用QUADAS标准评估文献的质量。计算具有95%置信区间(CI)的标准化平均差异(SMD)以评估联合效应。亚组分析,我们还对获得的信息进行了敏感性分析和发表偏倚检验.
结果：15项符合条件的研究包括1332例急性胰腺炎（AP）患者。合并分析显示,SAP患者血清抵抗素水平明显升高(SMD=0.78,95%CI:0.37~1.19,z=3.75,P=0.000)。SAP和轻症急性胰腺炎（MAP）患者的瘦素和脂联素水平差异无统计学意义（SMD=0.30，95％CI：-0.08至0.68，z=1.53，P=0.127，SMD=0.11，95％CI：-0.17至0.40，z=0.80，P=0.425）。在SAP患者中，内脂素水平与MAP患者无显着差异（SMD=1.20，95％CI：-0.48至2.88，z=1.40，P=0.162）。
结论：抵抗素水平升高与SAP的发展有关。抵抗素可以作为SAP的生物标志物，并有望作为治疗靶标。
方法：我们筛选了PubMed，EMBASE,WebofScienceandCochraneLibraryforarticlesonadipokinesandSAPbeforeJuly20,2023.使用QUADAS标准评估文献的质量。计算具有95%置信区间(CI)的标准化平均差异(SMD)以评估联合效应。亚组分析,我们还对获得的信息进行了敏感性分析和发表偏倚检验.
结果：15项符合条件的研究包括1332例急性胰腺炎（AP）患者。合并分析显示,SAP患者血清抵抗素水平明显升高(SMD=0.78,95%CI:0.37~1.19,z=3.75,P=0.000)。SAP和轻症急性胰腺炎（MAP）患者的瘦素和脂联素水平差异无统计学意义（SMD=0.30，95％CI：-0.08至0.68，z=1.53，P=0.127，SMD=0.11，95％CI：-0.17至0.40，z=0.80，P=0.425）。在SAP患者中，内脂素水平与MAP患者无显着差异（SMD=1.20，95％CI：-0.48至2.88，z=1.40，P=0.162）。
结论：抵抗素水平升高与SAP的发展有关。抵抗素可以作为SAP的生物标志物，并有望作为治疗靶标。
